Serum galactose-deficient immunoglobulin A1 in recurrent immunoglobulin a nephropathy after kidney transplantation: A meta-analysis

作者全名："Gong, Zhiyan; Tang, Jianying; Hu, Wei; Song, Xiaoyan; Liu, Xiyan; Mu, Jiao; Su, Yuanyuan"

作者地址："[Gong, Zhiyan] Chongqing Med Univ, Affiliated Hosp 1, Dept Ultrasound, Chongqing 400042, Peoples R China; [Tang, Jianying; Hu, Wei; Song, Xiaoyan; Mu, Jiao; Su, Yuanyuan] Chongqing Med Univ, Univ Town Hosp, Dept Nephrol, Chongqing 401331, Peoples R China; [Liu, Xiyan] Sci & Technol Innovat Ctr Jiangjin Dist, Chongqing 402260, Peoples R China"

通信作者："Su, YY (通讯作者)，Chongqing Med Univ, Univ Town Hosp, Dept Nephrol, Chongqing 401331, Peoples R China."

来源：TRANSPLANT IMMUNOLOGY

ESI学科分类：IMMUNOLOGY

WOS号：WOS:001001116400001

JCR分区：Q3

影响因子：1.6

年份：2023

卷号：79

期号：　

开始页：　

结束页：　

文献类型：Article

关键词：Gd-IgA1; IgA nephropathy; Recurrent glomerulonephritis; Kidney transplantation; Biomarker

摘要："Background: Immunoglobulin A nephropathy (IgAN) is a main cause of end stage renal disease (ESRD). Many IgAN patients with ESRD accept kidney allograft for renal replacement. However, disease recurrence occurs after transplantation. Galactose-deficient immunoglobulin A1(Gd-IgA1) has been proved to be a crucial biomarker in the primary IgAN population.Methods: This meta-analysis aimed to explore the association between serum Gd-IgA1 and IgAN recurrence after renal transplantation and was registered on PROSPERO: CRD42022356952; A literature search was performed and relevant studies were retrieved from the PubMed, Embase and Cochrane library databases from inception to April 27, 2023. The inclusion criteria were: 1) full-text studies; 2) patients with histological diagnosis of IgAN of their native kidneys who underwent kidney transplantation; 3) studies exploring the relationship between serum Gd-IgA1 and IgAN recurrence after kidney transplantation. The exclusion criteria were: 1) reviews, case reports, or non-clinical studies. 2) studies with insufficient original data or incomplete data. 3) studies with duplicated data. Study quality was assessed using Newcastle Ottawa Scale (NOS). Data were pooled using a random-effects model.Results: 8 full-text studies including 515 patients were identified. The Newcastle-Ottawa Scale (NOS) score ranged from 6 to 8. The standard mean difference (SMD) of the level of Gd-IgA1 was significantly higher in recurrence group than in non-recurrence group (SMD = 0.50,95%CI = 0.15-0.85, p = 0.005). Furthermore, GdIgA1 levels were higher in recurrence patients than in non-recurrence in both Europe subgroup (SMD 0.45, 95% CI: 0.08-0.82, p = 0.02) and Asia subgroup (SMD 0.90, 95%CI: 0.10-1.70, p = 0.03). However, pretransplant GdIgA1 levels showed no significant difference between recurrence and non-recurrence group (SMD 0.46, 95%CI: 0.06-0.99, p = 0.08) in anther subgroup analysis while posttransplant Gd-IgA1 levels were significantly higher in recurrence population than in non-recurrence (SMD 0.57, 95%CI 0.21 to 0.92, p = 0.002).Conclusions: This meta-analysis showed that posttransplant serum Gd-IgA1 levels are associated with IgAN recurrence after kidney transplantation; however, pretransplant serum Gd-IgA1 levels are not."

基金机构：　

基金资助正文：